Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Paul Johns
Trade Marks

Fresenius Adalimumab Switching Study Confirms Safety and Efficacy

Jun 28, 2024

On 28 June 2024, the results of a switching study on Fresenius Kabi’s® (MSB11022 adalimumab biosimilar) were published in Current Medical Research and Opinion, following presentation at the 2024 European Congress of Rheumatology (EULAR) earlier in June.  The study demonstrated that switching patients with rheumatoid arthritis from AbbVie’s Humira® (adalimumab) to Idacio® produced comparable results in terms of efficacy, safety and immunogenicity.   

The first Humira® biosimilar (Amgen’s Amjevita®) was launched in the US on 31 January 2023, with multiple additional biosimilars entering the US market in July 2023.  In February 2024, Teva and Alvotech’s Simlandi® was FDA approved as the first interchangeable, high concentration, citrate free adalimumab biosimilar. Simlandi was launched in the US in May 2024.